These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 32424876)

  • 21. Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis.
    Kim WY; Jung HY; Nam SJ; Kim TM; Heo DS; Kim CW; Jeon YK
    Virchows Arch; 2016 Nov; 469(5):581-590. PubMed ID: 27595782
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frequent expression of PD-L1 in BLS-type diffuse large B-cell lymphoma: implications for aggressiveness and immunotherapy.
    Yang CF; Yu YT; Wang SH; Chen YP; Chen TY; Hsu CY; Medeiros LJ; Chang KC
    Pathology; 2024 Apr; 56(3):367-373. PubMed ID: 38290893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nodal cytotoxic lymphoma spectrum: a clinicopathologic study of 66 patients.
    Kagami Y; Suzuki R; Taji H; Yatabe Y; Takeuchi T; Maeda S; Kondo E; Kojima M; Motoori T; Mizoguchi Y; Okamoto M; Ohnishi K; Yamabe H; Seto M; Ogura M; Koshikawa T; Takahashi T; Kurita S; Morishima Y; Suchi T; Nakamura S
    Am J Surg Pathol; 1999 Oct; 23(10):1184-200. PubMed ID: 10524519
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nodal cytotoxic peripheral T-cell lymphoma occurs frequently in the clinical setting of immunodysregulation and is associated with recurrent epigenetic alterations.
    Nicolae A; Bouilly J; Lara D; Fataccioli V; Lemonnier F; Drieux F; Parrens M; Robe C; Poullot E; Bisig B; Bossard C; Letourneau A; Missiaglia E; Bonnet C; Szablewski V; Traverse-Glehen A; Delfau-Larue MH; de Leval L; Gaulard P
    Mod Pathol; 2022 Aug; 35(8):1126-1136. PubMed ID: 35301414
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.
    Kataoka K; Miyoshi H; Sakata S; Dobashi A; Couronné L; Kogure Y; Sato Y; Nishida K; Gion Y; Shiraishi Y; Tanaka H; Chiba K; Watatani Y; Kakiuchi N; Shiozawa Y; Yoshizato T; Yoshida K; Makishima H; Sanada M; Onozawa M; Teshima T; Yoshiki Y; Ishida T; Suzuki K; Shimada K; Tomita A; Kato M; Ota Y; Izutsu K; Demachi-Okamura A; Akatsuka Y; Miyano S; Yoshino T; Gaulard P; Hermine O; Takeuchi K; Ohshima K; Ogawa S
    Leukemia; 2019 Jul; 33(7):1687-1699. PubMed ID: 30683910
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
    Xie M; Huang X; Ye X; Qian W
    Int Immunopharmacol; 2019 Dec; 77():105999. PubMed ID: 31704289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced PD-L1 Expression in LMP1-positive Cells of Epstein-Barr Virus-associated Malignant Lymphomas and Lymphoproliferative Disorders: A Single-cell Resolution Analysis With Multiplex Fluorescence Immunohistochemistry and In Situ Hybridization.
    Kume A; Shinozaki-Ushiku A; Kunita A; Kondo A; Ushiku T
    Am J Surg Pathol; 2022 Oct; 46(10):1386-1396. PubMed ID: 35605962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic impact of PD-L1 expression in primary gastric and intestinal diffuse large B-cell lymphoma.
    Ishikawa E; Nakamura M; Shimada K; Tanaka T; Satou A; Kohno K; Sakakibara A; Furukawa K; Yamamura T; Miyahara R; Nakamura S; Kato S; Fujishiro M
    J Gastroenterol; 2020 Jan; 55(1):39-50. PubMed ID: 31493237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.
    Choi E; Chang MS; Byeon SJ; Jin H; Jung KC; Kim H; Lee KL; Kim W; Park JH; Kim KH; Kim JS; Choi IS; Han DS; Ahn HS; Heo SC
    Diagn Pathol; 2020 Jun; 15(1):69. PubMed ID: 32498695
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinicopathological characteristics and prognosis of Epstein-Barr virus-associated gastric cancer.
    Li LL; Yu AY; Zhu M; Ma LY; Cao MH; Liu WL; Qin XB; Gao C; Han ZX; Wang HM
    Arch Virol; 2024 May; 169(5):114. PubMed ID: 38700535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Poor prognosis in Epstein-Barr virus-negative gastric cancer with lymphoid stroma is associated with immune phenotype.
    Cho CJ; Kang HJ; Ryu YM; Park YS; Jeong HJ; Park YM; Lim H; Lee JH; Song HJ; Jung HY; Kim SY; Myung SJ
    Gastric Cancer; 2018 Nov; 21(6):925-935. PubMed ID: 29627937
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PD-L1 and EBV LMP1 expressions in classic Hodgkin lymphomas and its correlation with clinicopathological parameters and prognosis.
    Özdemir S; Ton Ö; Kabukcuoğlu F
    Turk J Med Sci; 2022 Aug; 52(4):1013-1021. PubMed ID: 36326378
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.
    Hu LY; Xu XL; Rao HL; Chen J; Lai RC; Huang HQ; Jiang WQ; Lin TY; Xia ZJ; Cai QQ
    Chin J Cancer; 2017 Dec; 36(1):94. PubMed ID: 29246182
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD68-positive tumour associated macrophages, PD-L1 expression, and EBV latent infection in a high HIV-prevalent South African cohort of Hodgkin lymphoma patients.
    Antel K; Chetty D; Oosthuizen J; Mohamed Z; Van der Vyver L; Verburgh E
    Pathology; 2021 Aug; 53(5):628-634. PubMed ID: 33558066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Triple Positivity for EBV, PD-1, and PD-L1 Identifies a Very High Risk Classical Hodgkin Lymphoma.
    Ozturk V; Yikilmaz AS; Kilicarslan A; Bakanay SM; Akinci S; Dilek İ
    Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e375-e381. PubMed ID: 32295735
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinicopathological features of primary EB virus positive nodal T/NK cell lymphoma].
    Wang GN; Zhao WG; Zhang DD; Zhang YP; Huang XJ; Li WC
    Zhonghua Bing Li Xue Za Zhi; 2020 Oct; 49(10):1009-1014. PubMed ID: 32992414
    [No Abstract]   [Full Text] [Related]  

  • 37. Epstein-Barr virus-positive nodal peripheral T cell lymphomas: clinicopathologic and gene expression profiling study.
    Ha SY; Sung J; Ju H; Karube K; Kim SJ; Kim WS; Seto M; Ko YH
    Pathol Res Pract; 2013 Jul; 209(7):448-54. PubMed ID: 23735590
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytotoxic molecule-positive classical Hodgkin's lymphoma: a clinicopathological comparison with cytotoxic molecule-positive peripheral T-cell lymphoma of not otherwise specified type.
    Asano N; Kinoshita T; Tamaru J; Ohshima K; Yoshino T; Niitsu N; Tsukamoto N; Hirabayashi K; Izutsu K; Taniwaki M; Morishima Y; Nakamura S
    Haematologica; 2011 Nov; 96(11):1636-43. PubMed ID: 21859738
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of cytotoxic proteins in peripheral T-cell and natural killer-cell (NK) lymphomas: association with extranodal site, NK or Tgammadelta phenotype, anaplastic morphology and CD30 expression.
    Kanavaros P; Boulland ML; Petit B; Arnulf B; Gaulard P
    Leuk Lymphoma; 2000 Jul; 38(3-4):317-26. PubMed ID: 10830738
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TLR9 expression is associated with PD-L1 expression and indicates a poor prognosis in patients with peripheral T-cell lymphomas.
    Qian J; Meng H; Lv B; Wang J; Lu Y; Li W; Zhao S
    Pathol Res Pract; 2020 Mar; 216(3):152703. PubMed ID: 31879046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.